JP2023182689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023182689A5 JP2023182689A5 JP2023169033A JP2023169033A JP2023182689A5 JP 2023182689 A5 JP2023182689 A5 JP 2023182689A5 JP 2023169033 A JP2023169033 A JP 2023169033A JP 2023169033 A JP2023169033 A JP 2023169033A JP 2023182689 A5 JP2023182689 A5 JP 2023182689A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid number
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021072429 | 2021-04-22 | ||
| JP2021072429 | 2021-04-22 | ||
| JP2023515503A JP7365654B2 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
| PCT/JP2022/018350 WO2022224997A1 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515503A Division JP7365654B2 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023182689A JP2023182689A (ja) | 2023-12-26 |
| JP2023182689A5 true JP2023182689A5 (enExample) | 2025-04-28 |
Family
ID=83722348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515503A Active JP7365654B2 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
| JP2023169033A Pending JP2023182689A (ja) | 2021-04-22 | 2023-09-29 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515503A Active JP7365654B2 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12227586B2 (enExample) |
| EP (1) | EP4327823A4 (enExample) |
| JP (2) | JP7365654B2 (enExample) |
| KR (1) | KR20230171465A (enExample) |
| CN (1) | CN117222672A (enExample) |
| AR (1) | AR125398A1 (enExample) |
| AU (1) | AU2022262542A1 (enExample) |
| BR (1) | BR112023021950A2 (enExample) |
| CA (1) | CA3217637A1 (enExample) |
| CL (1) | CL2023003100A1 (enExample) |
| CO (1) | CO2023015630A2 (enExample) |
| CR (1) | CR20230490A (enExample) |
| DO (2) | DOP2023000230A (enExample) |
| EC (1) | ECSP23087918A (enExample) |
| IL (1) | IL307744A (enExample) |
| MX (1) | MX2023012432A (enExample) |
| PE (1) | PE20241357A1 (enExample) |
| SA (1) | SA523451235B1 (enExample) |
| TW (1) | TW202309083A (enExample) |
| WO (1) | WO2022224997A1 (enExample) |
| ZA (1) | ZA202310292B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250304706A1 (en) | 2022-05-12 | 2025-10-02 | Astellas Pharma Inc. | Anti-taa/anti-cd3 multispecific antibody |
| WO2024085166A1 (ja) * | 2022-10-19 | 2024-04-25 | アステラス製薬株式会社 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP3770174A1 (en) | 2005-10-11 | 2021-01-27 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| WO2008011756A1 (fr) | 2006-07-19 | 2008-01-31 | Jen-Shyan Chen | Équipement d'éclairage à diodes électroluminescentes haute puissance avec module de dissipation thermique efficace |
| EP2138576A4 (en) | 2007-03-16 | 2011-02-23 | Kyowa Hakko Kirin Co Ltd | ANTI-CLAUDIN-4 ANTIBODY |
| LT2346994T (lt) | 2008-09-30 | 2022-03-10 | Ablexis, Llc | Knock-in pelė, skirta chimerinių antikūnų gamybai |
| WO2014132647A1 (ja) * | 2013-03-01 | 2014-09-04 | 公益財団法人ヒューマンサイエンス振興財団 | 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー |
| CA2943943C (en) | 2014-04-07 | 2023-01-10 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| AU2016258977C1 (en) | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| WO2019048040A1 (en) | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| JP2021510064A (ja) * | 2018-01-05 | 2021-04-15 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| AU2019235900B2 (en) * | 2018-03-14 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
| IL280002B2 (en) * | 2018-07-12 | 2025-05-01 | F Star Beta Ltd | Antibody molecules that bind CD137 and OX40 |
-
2022
- 2022-04-21 AU AU2022262542A patent/AU2022262542A1/en active Pending
- 2022-04-21 KR KR1020237039211A patent/KR20230171465A/ko active Pending
- 2022-04-21 CA CA3217637A patent/CA3217637A1/en active Pending
- 2022-04-21 CR CR20230490A patent/CR20230490A/es unknown
- 2022-04-21 WO PCT/JP2022/018350 patent/WO2022224997A1/ja not_active Ceased
- 2022-04-21 PE PE2023002906A patent/PE20241357A1/es unknown
- 2022-04-21 TW TW111115193A patent/TW202309083A/zh unknown
- 2022-04-21 AR ARP220101032A patent/AR125398A1/es unknown
- 2022-04-21 EP EP22791768.9A patent/EP4327823A4/en active Pending
- 2022-04-21 IL IL307744A patent/IL307744A/en unknown
- 2022-04-21 BR BR112023021950A patent/BR112023021950A2/pt active IP Right Grant
- 2022-04-21 CN CN202280029125.XA patent/CN117222672A/zh active Pending
- 2022-04-21 MX MX2023012432A patent/MX2023012432A/es unknown
- 2022-04-21 US US18/556,606 patent/US12227586B2/en active Active
- 2022-04-21 JP JP2023515503A patent/JP7365654B2/ja active Active
-
2023
- 2023-09-29 JP JP2023169033A patent/JP2023182689A/ja active Pending
- 2023-10-18 CL CL2023003100A patent/CL2023003100A1/es unknown
- 2023-10-19 DO DO2023000230A patent/DOP2023000230A/es unknown
- 2023-10-22 SA SA523451235A patent/SA523451235B1/ar unknown
- 2023-11-03 ZA ZA2023/10292A patent/ZA202310292B/en unknown
- 2023-11-20 CO CONC2023/0015630A patent/CO2023015630A2/es unknown
- 2023-11-21 EC ECSENADI202387918A patent/ECSP23087918A/es unknown
-
2025
- 2025-01-14 US US19/020,859 patent/US20250154272A1/en active Pending
- 2025-09-09 DO DO2025000223A patent/DOP2025000223A/es unknown